Steglujan is an anti-diabetic drug owned by Merck Sharp Dohme. The active ingredients of this drug are Ertugliflozin and Sitagliptin Phosphate. Steglujan was first authorized for market use on 19 December, 2017.
Steglujan has a total of 7 drug patents, out of which 2 have already expired. The remaining patents are set to expire between 2023 and 2030. The generic version of Steglujan is expected to be available after the expiry of the last patent on 21 October, 2030.
Steglujan is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The effectiveness of Steglujan is due to its active ingredients - Ertugliflozin and Sitagliptin Phosphate.
Steglujan holds a number of patents, with the latest set to expire on 21 October, 2030. This date suggests when we might expect the release of Steglujan generic. Below are the details of the patent: